Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities.

Antimicrobial Agents and Chemotherapy
T KamimuraS Kuwahara

Abstract

FK 749 is a new parenteral cephalosporin derivative which is more active against various gram-negative bacilli, including the opportunistic pathogens such as Enterobacter, Citrobacter species, and Serratia marcescens, than cephalosporins and cephamycins such as cefotiam, cefamandole, cefuroxime, cefotaxime, and cefmetazole. FK 749 was especially active against gram-negative organisms resistant to these related antibiotics. FK 749 was more potent in bactericidal activity than the other antibiotics, and the activity was clearly enhanced in the presence of 90% defibrinated rabbit blood. The therapeutic effect of subcutaneously injected FK 749 in mice infected with various gram-negative bacilli was far superior to that of cefotiam, cefamandole, cefuroxime, and cefmetazole and was almost the same as that of cefmetazole in mice infected with Staphylococcus aureus and that of ticarcillin in mice infected with Pseudomonas aeruginosa. FK 749 has, in general, nearly the same in vitro and in vivo antibacterial activities as cefotaxime. The former had more potent bactericidal activity in the presence of the blood than the latter and showed more excellent therapeutic effect than cefotaxime against infections caused by large inoculum sizes.

References

Oct 1, 1978·Antimicrobial Agents and Chemotherapy·K TsuchiyaT Nishi
Jul 1, 1976·Antimicrobial Agents and Chemotherapy·M NishidaK Miki
Jan 1, 1974·Antimicrobial Agents and Chemotherapy·H R OnishiE O Stapley
Jan 1, 1974·Antimicrobial Agents and Chemotherapy·H Wallick, D Hendlin

❮ Previous
Next ❯

Citations

Jan 1, 1984·Infection·M O HussonH Leclerc
Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Zavala TrujilloM Renteria
Jan 1, 1985·International Urology and Nephrology·M TripiG Carella
Jan 1, 1992·Diagnostic Microbiology and Infectious Disease·R N JonesM Bale
Oct 1, 1993·Diagnostic Microbiology and Infectious Disease·M S BarrettM E Erwin
Jan 1, 1985·Biotechnology & Genetic Engineering Reviews·H Umezawa
Feb 1, 1980·Antimicrobial Agents and Chemotherapy·T MurakawaM Nishida
Dec 1, 1980·Antimicrobial Agents and Chemotherapy·P AngehrnR L Then
Jul 1, 1981·Antimicrobial Agents and Chemotherapy·E YabuuchiA Ohyama
Aug 1, 1981·Antimicrobial Agents and Chemotherapy·G P BodeyA M Hinkle
Nov 1, 1981·Antimicrobial Agents and Chemotherapy·I H PatelS A Kaplan
Nov 1, 1981·Antimicrobial Agents and Chemotherapy·M W Drulak, A W Chow
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·H L Muytjens, J van der Ros-van de Repe
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·J W GnannC G Cobbs
Aug 1, 1982·Antimicrobial Agents and Chemotherapy·M OhkawaK Kuroda
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·T KamimuraS Kuwahara
Oct 1, 1986·Antimicrobial Agents and Chemotherapy·M V BorobioE J Perea
Jul 1, 1987·Antimicrobial Agents and Chemotherapy·Y UtsuiS Mitsuhashi
May 1, 1991·Antimicrobial Agents and Chemotherapy·M E ErwinD M Johnson
Jun 1, 1981·The British Journal of Venereal Diseases·E H SngK L Yeo
Jul 1, 1984·European Journal of Drug Metabolism and Pharmacokinetics·M O DecroixB Flouvat
Jan 1, 1992·Infection·H Knothe, P M Shah
Apr 1, 1983·Journal of Pharmaceutical Sciences·I UedaJ Kozatani
Feb 1, 1986·American Journal of Surgery·D E Fry
Jan 1, 1981·Medicinal Research Reviews·H Nakano
Apr 1, 1982·British Journal of Clinical Pharmacology·J N Longrigg
Oct 1, 1981·Journal of Clinical Pharmacology·N NakashimaK Nishijima
Sep 1, 1995·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Anna KingIan Phillips
May 1, 1994·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M BlancaJ Fernandez
Sep 1, 1983·Drug Intelligence & Clinical Pharmacy·P GarzoneV L Yu
May 1, 1982·British Journal of Clinical Pharmacology·D Greenwood, R Slack
Mar 1, 2011·Analytical Methods : Advancing Methods and Applications·Mir Reza MajidiBehnam Hafezi
Feb 1, 1984·Antimicrobial Agents and Chemotherapy·G D OverturfC Shikuma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.